Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Fundamental Analysis
Translational Development Acquisition Corp. (TDACW) shows weak financial fundamentals with a PE ratio of 28.68, profit margin of 0.00%, and ROE of 5.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 32.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TDACW's fundamental strength across five key dimensions:
Efficiency Score
WeakTDACW struggles to generate sufficient returns from assets.
Valuation Score
ModerateTDACW shows balanced valuation metrics.
Growth Score
WeakTDACW faces weak or negative growth trends.
Financial Health Score
ModerateTDACW shows balanced financial health with some risks.
Profitability Score
WeakTDACW struggles to sustain strong margins.
Key Financial Metrics
Is TDACW Expensive or Cheap?
P/E Ratio
TDACW trades at 28.68 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, TDACW's PEG of -0.99 indicates potential undervaluation.
Price to Book
The market values Translational Development Acquisition Corp. at -27.90 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -245.42 times EBITDA. This is generally considered low.
How Well Does TDACW Make Money?
Net Profit Margin
For every $100 in sales, Translational Development Acquisition Corp. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.00 in profit for every $100 of shareholder equity.
ROA
Translational Development Acquisition Corp. generates $3.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.37 in free cash annually.
FCF Yield
TDACW converts 2.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
28.68
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.99
vs 25 benchmark
P/B Ratio
Price to book value ratio
-27.90
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How TDACW Stacks Against Its Sector Peers
| Metric | TDACW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 28.68 | 18.59 | Worse (Expensive) |
| ROE | 5.00% | 801.00% | Weak |
| Net Margin | 0.00% | -498.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.98 | Strong (Low Leverage) |
| Current Ratio | 0.07 | 661.40 | Weak Liquidity |
| ROA | 3.50% | -21324.00% (disorted) | Weak |
TDACW outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Translational Development Acquisition Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical